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Background: Body composition is an important predictor of drug toxicity and outcome. Ipilimumab (Ipi), a monoclonal antibody
used to treat metastatic melanoma, has specific toxicities. No validated biomarkers that predict Ipi toxicity and efficacy exist. Also,
the impact of Ipi on body composition has not been established.
Methods: Patients with metastatic melanoma treated with Ipi between 2009 and 2015 were included. Body composition was
assessed by computed tomography at baseline and after four cycles of Ipi. Sarcopenia and low muscle attenuation (MA)
were defined using published cut-points. All adverse events (AEs) and immune-related AEs (irAEs) were recorded (Common
Terminology Criteria For Adverse Event V.4.0).
Results: Eighty-four patients were included in this study (62% male, median age 54 years). At baseline, 24% were sarcopenic and
33% had low MA. On multivariate analysis, sarcopenia and low MA were significantly associated with high-grade AEs (OR¼ 5.34,
95% CI: 1.15–24.88, P¼ 0.033; OR¼ 5.23, 95% CI: 1.41–19.30, P¼ 0.013, respectively), and low MA was associated with high-grade
irAEs (OR¼ 3.57, 95% CI: 1.09–11.77, P¼ 0.036). Longitudinal analysis (n¼ 59) revealed significant reductions in skeletal muscle
area (SMA), total body fat-free mass, fat mass (all Po0.001) and MA (P¼ 0.030). Mean reduction in SMA was 3.3%/100 days
(95% CI:  4.48 to  1.79%, Po0.001). A loss of SMA X7.5%/100 days (highest quartile) was a significant predictor of overall
survival in multivariable Cox regression analysis (HR: 2.1, 95% CI: 1.02–4.56, P¼ 0.046).
Conclusions: Patients with sarcopenia and low MA are more likely to experience severe treatment-related toxicity to Ipi. Loss of
muscle during treatment was predictive of worse survival. Treatments to increase muscle mass and influence outcome warrant
further investigation.
In Europe, malignant melanoma of the skin is the seventh and
tenth most common cancer diagnosed in women and men,
respectively (International Agency for Research on Cancer, Cancer
Fact Sheets 2012). Traditionally, patients with metastatic mela-
noma have been known to have a dismal prognosis, with a median
overall survival of 8–10 months and a 5-year survival rate of 10%
(Garbe et al, 2011). Curative surgical options are available in the
early stages of the disease; however, once the disease has progressed
to an advanced stage, treatment options are largely confined to
systemic therapy and long-term remission is uncommon.
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In the modern era, due in part to advances in therapies that
stimulate an immune-mediated antitumour response, more treat-
ment options are available for those with advanced melanoma.
Ipilimumab, a novel anticytotoxic T-cell lymphocyte-4 monoclonal
antibody, was the first of its kind to demonstrate a significant survival
benefit in previously treated metastatic melanoma patients (median
OS 10.1 months vs 6.4 months in gp100 vaccine group; 1- and 2-year
survival rates of 45.6% and 23.5%, respectively, in the ipilimumab
arm) (Hodi et al, 2010). Following the release of this phase III data,
ipilimumab was approved by the US Food and Drug Administration
and by the European Medicines Association at a dose of 3 mg kg 1
body weight in patients with metastatic melanoma.
Ipilimumab augments T-cell activation and proliferation with
the goal of reducing immune tolerance to cancer-specific antigens
(Robert and Ghiringhelli, 2009). As a result, ipilimumab can result
in an activation of immune responses against normal tissue, which
can result in ‘immune-related adverse events (irAEs)’ (Hodi et al,
2010). The irAEs have been well described. Approximately 61% of
patients treated with ipilimumab experience an irAE (any grade),
whereas 17% of patients experience a high-grade irAE (grades III
and IV) (Bertrand et al, 2015). IrAEs most commonly affect the
gastrointestinal (GI) tract, the skin or endocrine glands (Hodi et al,
2010; Bertrand et al, 2015). Such adverse effect can be treated
effectively with immunosuppressive agents (Weber et al, 2012).
To date, little is known in relation to factors predicting ipilimumab
toxicity.
Over the past decade, sarcopenia (low muscle mass) and its
relationship to adverse clinical outcomes has been extensively
studied and shown to be associated with increase length of hospital
stay (Pichard et al, 2004), postoperative infections (Lieffers et al,
2012), functional impairment and decreased survival in both
malignant (Tan et al, 2009; Martin et al, 2013) and non-malignant
(Montano-Loza et al, 2012) populations. Sarcopenia and its
relationship to anticancer treatment toxicity has been particularly
topical in the literature, and studies have consistently demon-
strated that sarcopenia is associated with poorer treatment
tolerance and increased prevalence of dose-limiting toxicity
(DLT) to many anticancer/chemotherapeutic drugs, for example,
epirubicin (Prado et al, 2011), capecitabine (Prado et al, 2009),
sunitinub (Huillard et al, 2013; Cushen et al, 2014), 5-FU and
leucovorin (Prado et al, 2007). More recently, low muscle
attenuation (MA), which refers to a poor quality skeletal muscle
(increased intramuscular adipose tissue) has been the focus of
much research. Low MA has been identified as a predictor of
reduced survival in renal cell carcinoma (Antoun et al, 2013b)
and stage III melanoma (Sabel et al, 2011), as well as lung and
GI malignancies (Martin et al, 2013; Blauwhoff-Buskermolen
et al, 2016).
To our knowledge, the association between altered/abnormal
body composition, that is, sarcopenia and low MA, and the
incidence of treatment-related AEs to ipilimumab has not yet been
reported. With increasing use of ipilimumab in clinical practice,
there is an urgent need for potential biomarkers that are predictive
of treatment toxicity. The primary aim of this study was to
investigate if body composition, specifically sarcopenia and low
MA, assessed by computed tomography (CT) could predict toxicity
to ipilimumab in patients with metastatic melanoma. A secondary
aim of this study was to determine the changes in body
composition that occur during treatment and to assess if these
changes impact on survival.
MATERIALS AND METHODS
Study population. We performed a retrospective medical record
review of all consecutive adult patients treated with ipilimumab at
two university teaching hospitals between the years of 2009 and
2015. Patients were excluded from this study if they lacked an
evaluable pre-treatment CT image. This study was approved by the
local ethics committee and conducted according to good clinical
practice and applicable laws.
Clinical details. Clinical and pathological data was collected by a
retrospective chart review, including information on patient
demographics, primary tumour site/stage, the extent of metastatic
disease, biochemistry results and oncological treatment. Patient’s
date of death (if present) or date of last follow-up was recorded.
Anthropometry and body composition. Weight and height
closest to the initiation of cycle 1 of treatment was recorded from
the medical charts. Body mass index (BMI) was calculated (weight
(kg) height (m 2)).
Pre- and post-treatment CT images taken as part of routine
patient care were accessed from the hospitals electronically stored
database. Body composition was evaluated using CT images, as
described previously (Heymsfield et al, 1997). The third lumbar
vertebrae (L3) was chosen as the standard landmark (Shen et al,
2004) and two consecutive transverse CT images where both
transverse processes were clearly visible were analysed using the
OsiriX software version 4.1.1 (Pixmeo, Geneva, Switzerland) and
the average result reported. Different tissue compartments were
manually outlined and segmentation of the skeletal muscle and
adipose tissue was based on Hounsfield unit (HU) thresholds
( 29 to þ 150, and  30 to  190 HU, respectively
(Mitsiopoulos et al, 1998). Cross-sectional areas (cm2) for muscle
and adipose tissue were automatically calculated by summing
tissue pixels and multiplying by pixel surface area after applying
HU thresholds. Mean MA is reported for the entire muscle area at
L3. Anonymised CT images were analysed by the two trained study
assessors (LD and SC) who were blinded to the order of images
(pre- and post-ipilimumab treatment). Pre-treatment images were
taken before treatment administration (mean 39±31 days). Post-
treatment images were taken after the final dose of ipilimumab was
administered (mean 35±31 days). The mean number of days
between the two scans was 146±40 days. To account for variation
in the exact duration of scan intervals, changes in tissue are
expressed as % change/100 days to provide a standard measure for
all patients.
The lumbar cross-sectional areas of muscle and fat are linearly
related to whole-body measures (Shen et al, 2004). Estimates of
whole-body fat mass (FM) and fat-free mass (FFM) were calculated
using published regression equations as follows (Mourtzakis et al,
2008): FFM (kg)¼ 0.3 (skeletal muscle cross-sectional area at L3
(cm2))þ 6.06; r2¼ 0.88, FM (kg)¼ 0.042 (Adipose tissue cross-
sectional area at L3 (cm2))þ 11.2; r2¼ 0.77. Gender- and BMI-
specific cut-points were used to define sarcopenia and low MA
(Martin et al, 2013).
Treatment tolerability. Toxicity profiles were recorded on all
patients by reviewing patient’s medical notes. Toxicity was
recorded across all administered cycles of ipilimumab. The
standard dose for ipilimumab is 3 mg kg 1 body weight adminis-
tered intravenously over a 90-min period every 3 weeks for four
doses. Adverse events were classified according to National Cancer
Institute Common Terminology Criteria for Adverse Events
(CTCAE), version 4.0. For further analyses, toxicity was divided
into grades I–II and grades III–IV. An irAE was defined as an AE
that was associated with exposure to ipilimumab and that was
consistent with an immune-related phenomenon. The irAEs
recorded were those most commonly reported. A high-grade
AE/irAE was defined as a grade III–IV toxicity. A high-grade AE
included all high-grade AEs, both general and immune-related
high-grade AEs. Any dose delays or early cessation of treatment as
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a result of significant toxicity (grades III–IV) was recorded, and in
this study it was defined as a DLT.
Statistical assessment. Statistical analysis was completed using
SPSS (version 21.0, SPSS Inc., Chicago, IL, USA). Data are
expressed as mean±s.d. or median (IQR) where appropriate.
Comparisons between groups of patients were assessed using
w2 test for categorical variables and unpaired t-tests and Mann–
Whitney U-tests to test for differences between continuous
variables. Paired t-tests were used to assess changes in body
composition. The McNemar’s test was to test for significances in
paired categorical data.
Logistic regression analyses were used to test associations
between treatment toxicity and measures of body composition
(baseline sarcopenia vs not sarcopenic and low MA vs without low
MA). Variables that had significance of Pp0.25 on univariate
analysis were eligible for inclusion in multivariate analysis.
Survival curves were constructed using the Kaplan–Meier
technique and log-rank test was used to compare survival between
groups of patients. Survival was measured from the date of the
baseline (pre-treatment) CT image until the date of death or
censored date (study completion). Median follow-up time (time in
study) for the entire cohort was 12.8 months [IQR: 5.45–21.7
months; 9.2 months (IQR 4.8–15.3 months) for patients who had
died and 24.1 months for censored cases (IQR 15.5–33.4 months)]
and 70% of patients had died by completion of the study. Cox
proportional hazards analyses was performed, and hazard ratios
(HR) with 95% confidence intervals (CI) calculated. All P-values
were two sided, and the level of significance was Po0.05.
RESULTS
Participants. From July 2010 to July 2015, 96 patients received
ipilimumab, of which 84 patients met the criteria for study analysis
(12 patients lacked an evaluable CT image). MA analysis was
carried out on all patients with a contrast-enhanced CT image
(n¼ 72).
Patient characteristics. Baseline characteristics are presented in
Table 1. In brief, among the 84 patients studied, 62% were male
with a median age of 54 years (IQR 43–66 years). The majority of
patients (79%) had stage M1c metastatic disease, with the most
common metastatic sites being lung (70%) and liver (41%).
Ipilimumab was first-line treatment in 34.5% of patients.
Anthropometry. Table 2 describes the body composition features
of the cohort. Fifty-nine patients (70%) were considered over-
weight or obese (BMI X25 kg m 2), while very few (only two
patients) were clinically underweight by WHO standards. Twenty
patients (24%) were sarcopenic (20 of 84) and 24 (24 of 72)
(33.3%) were considered to have a low MA.
Sarcopenic patients differed significantly from non-sarcopenic
patients as expected with a lower skeletal muscle area (SMA) (161.2
vs 121.4 cm2, Pp0.001), skeletal muscle index (SMI) (54.7 vs
41.1 cm2 m 2, Po0.001) and FFM (54.4 vs 42.5 kg, Po0.001).
Sarcopenic patients had a lower mean MA (41.2 vs 34.7 HU)
(P¼ 0.008), and a higher prevalence of those with low MA (64.7%
vs 23.6%, P¼ 0.004). A trend was observed that sarcopenic patients
were older (60 vs 53 years, P¼ 0.087).
Patients with low MA were significantly older (mean 64 vs 48
years, Pp0.001) and had a significantly lower SMA (126.11 vs
156.54 cm2, Pp0.001), SMI (44.75 vs 52.88 cm2 m 2, Pp0.001)
and FFM (53.02 vs 46.5 kg, P¼ 0.022) compared with those
without low MA, as a result patients’ with low MA had a higher
prevalence of sarcopenia (45.8% vs 12.5%, P¼ 0.004). The mean
HU in those with and without low MA was 30.3 vs 44.4 HU,
respectively (Pp0.001). Patients with sarcopenia or low MA and
those without were otherwise similar in terms of clinical features.
No significant association was observed between the prevalence of
sarcopenia or low MA and the extent of metastatic disease.
Patients with a BMI X25 kg m 2, as expected weighed
more (90.3 vs 65.8 kg, Pp0.001) and had a significantly higher
SMI (54.2 vs 45.01 cm2 m 2, Pp0.001) compared with those with
a BMI o25 kg m 2; however, these patients had a significantly
lower MA (37.45 HU vs 44.64 HU, P¼ 0.001). Patients were
otherwise similar.
The incidence of high-grade (grades III–IV) AEs and irAEs. The
frequencies of ipilimumab-associated AEs and irAEs are shown in
Table 3. In our study, 60 (71%) patients experienced an AE and 47
(56%) experienced an irAE. Many AE reported were of grades I–II;
however, 35 (42%) patients experienced a high-grade AE, with 25
(30%) patients experiencing a high-grade irAE.
Sarcopenia, low MA and treatment tolerability. No significant
difference was observed in the prevalence of any grade I–II AEs or
grade I–II irAEs in patients with sarcopenia or low MA and in
those without (results not shown).
Patients with sarcopenia experienced more high-grade AEs
compared with their non-sarcopenic counterparts (65% vs 34%,
P¼ 0.030, univariate OR¼ 3.54, 95% CI: 1.23–10.17, P¼ 0.019)
and appeared to be more susceptible to a high-grade irAE (45% vs
25%); however, this did not reach statistical significance. When
considering individual high-grade AEs or irAEs separately, only
fatigue was significantly more prevalent in sarcopenic patients
(35% vs 9.4%, P¼ 0.011) (Supplementary Table 1). Patients with
low MA were more likely to experience a high-grade AE (75% vs
31%, P¼ 0.001, univariate OR¼ 7.46, 95% CI: 2.45–22.66,
Pp0.001), and more likely to experience a high-grade irAE (54%
vs 23%, P¼ 0.017, univariate OR¼ 4.49, 95% CI: 1.64–13.5,
P¼ 0.004). Patients with low MA had a higher incidence of colitis
(16.7% vs 2.1%, P¼ 0.039) (Supplementary Table 1).



















Ipilimumab first-line treatment 29 (34.5)
Number of doses of ipilimumab
Median 4
Range 1–4
Completed all four cycles of ipilimumab 60 (71)
Early cessation of treatment 24 (29)
Progression of disease 10 (12)
Treatment-related toxicity 12 (14)
Death 2 (3)
Abbreviation: IQR¼ interquartile range.
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On multivariate logistic regression analysis (Table 4) including
age, gender, BMI, sarcopenia and low MA, patients with
sarcopenia, low MA and a BMI X25 kg m 2 were at a significantly
increased risk of experiencing a high-grade AE (OR¼ 5.34, 95%
CI: 1.15–24.88, P¼ 0.033; OR¼ 5.23, 95% CI: 1.41–19.30,
P¼ 0.013; and OR¼ 4.01, 95% CI: 1.03–15.69, P¼ 0.046, respec-
tively). Patients with low MA were at a significantly increased risk
of experiencing a high-grade irAE (OR¼ 3.57, 95% CI: 1.09–11.77,
P¼ 0.036).
Sarcopenia, low MA and the incidence of a DLT. Overall, 15
patients (18%) experienced a DLT. Twelve patients (14.3%)
discontinued ipilimumab treatment because of a high-grade irAE,
with the most common events being skin toxicity (rash) (four
patients), diarrhoea (two patients) and colitis (two patients). Six
patients experienced a dose delay, while three patients experienced
both a dose delay and early cessation of treatment. Patients who
experienced a DLT were older (53 years vs 63 years, P¼ 0.017) and
had a significantly lower mean MA (41.2 HU vs 33.4 HU,
P¼ 0.003). The prevalence of DLT was more common in patients
with low MA compared with those without low MA (37.5% or 9 of
24 vs 10.4% or 5 of 48, P¼ 0.011). Sarcopenic patients appeared to
be more susceptible to experience a DLT (25.0% or 5 of 20 vs 15.6%
or 10 of 64, respectively); however, this did not reach statistical
significance.
Changes in body composition. Longitudinal changes in body
composition during four cycles of ipilimumab were examined in
patients where both pre- and post-treatment CT images were
available (n¼ 59).
Significant decreases were observed across all body composition
parameters (see Table 5). The mean decrease in SMA was 3.3%
(s.d. 5.84%) (95% CI:  4.48 to  1.79%, Pp0.001) per 100 days.
The prevalence of sarcopenia increased from 17% (or 10 of 59) at
baseline to 32% (or 19 of 59) by the second CT scan in this
subgroup of patients.
Effect of change on survival. Patients with a muscle loss of
X7.5%/100 days (quartile four; highest muscle loss) had
significantly lower overall survival compared with those with a
muscle loss o7.5%/100 days (quartiles 1–3; minor muscle loss/
stable or gain). The median survival was 9.5 months (95% CI:
1.5–17.6 months) for those with the highest muscle loss (X7.5%)
vs 21.8 months (95% CI: 14.3–29.4 months) in those with a muscle
loss o7.5%/100 days (log rank; P¼ 0.029; univariate Cox
regression, HR: 2.14, 95% CI: 1.06–4.28, P¼ 0.033) (Figure 1).
On multivariate analysis, muscle loss of X7.5% remained
Table 2. Nutritional characteristics, values given as mean (s.d.), unless stated otherwise
Characteristic Males (n¼52) Females (n¼32) Total (n¼84)
BMI (kg m 2), median (IQR) 27.6 (24.9–30.1) 26.5 (23.3–29.5) 26.9 (24.4–30.4)
Underweight (p18.5 kg m2), n (%) 0 (0) 2 (6.3) 2 (2)
Normal (18.5–24.9 kg m2), n (%) 13 (25) 10 (31) 23 (28)
Overweight (25–29.9 kg m 2) n (%) 24 (46) 14 (44) 38 (45)
Obese (X30.0 kg m2), n (%) 15 (29) 6 (19) 21 (25)
Skeletal muscle area (cm2) 174.7 (32.1) 114.3 (13.3) 151.6 (39.6)
Skeletal muscle index (cm2 m2) 56.4 (9.6) 43.4 (5.2) 51.4 (10.4)
Sarcopenia, n (%) 10 (19.2) 10 (31.3) 20 (23.8)
Muscle attenuationa (HU) 39.8 (7.9) 38.8 (10.2) 39.4 (8.9)
Low muscle attenuationa, n (%) 12 (27.9) 12 (41.4) 24 (33.3)
Adipose tissue area (cm2) 401.3 (182.5) 259.4 (133.6) 350.2 (179.2)
Adipose tissue index (cm2 m 2) 129.0 (57.5) 98.8 (50.4) 118.2 (56.6)
Estimated FFM (kg) 58.5 (9.6) 40.3 (4.0) 51.6 (11.9)
Estimated FM (kg) 28.1 (7.7) 22.1 (5.6) 25.9 (7.5)
Abbreviations: BMI¼body mass index; CT¼ computed tomography; FM¼ fat mass; FFM¼ fat-free mass; HU¼Hounsfield units; IQR¼ interquartile range; MA¼muscle attenuation;
s.d.¼ standard deviation.
aMA assessed for 72 patients (43 men and 29 women). Twelve patients (3 women and 9 men) lacked suitable contrast-enhanced CT images for MA analysis.











Any adverse event 60 (71.4) 53 (63.1) 35 (41.7)
Any immune-related event 47 (56.0) 39 (46.4) 25 (29.8)
General adverse event
Fatigue 38 (45.2) 25 (29.8) 13 (15.5)
Nausea 15 (17.9) 15 (17.9) 0 (0)
Vomiting 6 (7.2) 5 (6.0) 1 (1.2)
Constipation 7 (8.3) 5 (6.0) 2 (2.4)
Abdominal pain 3 (3.6) 1 (1.2) 2 (2.4)
Anorexia 12 (14.3) 11 (13.1) 1 (1.2)
Pyrexia 8 (9.5) 7 (8.3) 1 (1.2)
Headache 4 (4.8) 4 (4.8) 0 (0)
Cough 4 (4.8) 4 (4.8) 0 (0)
Dyspnoea 2 (2.4) 2 (2.4) 0 (0)
Anaemia 13 (15.5) 10 (11.9) 3 (3.6)
Immune-related adverse event
Dermatologic/skin
Pruritus 8 (9.5) 8 (9.5) 0 (0)
Rash 20 (23.8) 13 (15.5) 7 (8.3)
Gastrointestinal
Diarrhoea 24 (28.5) 20 (23.8) 4 (4.8)
Colitis 6 (7.2) 1 (1.2) 5 (6.0)
Endocrine
Hypothyroidism 2 (2.4) 2 (2.4) 0 (0)
Hypopituitarism 6 (7.1) 1 (1.2) 5 (6.0)
Hypophysitis 1 (1.2) 0 (0) 1 (1.2)
Adrenal insufficiency 1 (1.2) 0 (0) 1 (1.2)
Abnormal hepatic function 1 (1.2) 0 (0) 1 (1.2)
Musculoskeletal
Arthritis 8 (9.6) 5 (6.0) 3 (3.6)
Othera 20 (23.8) 11 (13.0) 9 (10.7)
aOral toxicity (mucositis, ulcers) grades I–II (7.1%), pericarditis grade III (1.2%), sarcoidosis
grade III (1.2%), ocular toxicity (conjunctivitis, blurred vision, dry eyes) grades I–II (4.8%),
lower limb weakness grade II (1.2%), neuropathy grade II (1.2%), ataxia grade II (2.4%), ataxia
grade III (1.2%), confusion grade III (2.4%) and grade V sepsis (1.2%).
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independently associated with shorter survival when adjusted for
gender, age (o65 vs 465 years) and stage of disease (M1c vs M1a
or M1b) as potential confounders (HR: 2.1, 95% CI: 1.02–4.56,
P¼ 0.046). Neither sarcopenia nor low MA at baseline was
associated with shorter survival.
DISCUSSION
To our knowledge, this is the first study to examine the
relationship between body composition and ipilimumab toxicity
in patients with metastatic melanoma. Our findings point to
sarcopenia and low MA as potential sources of variation in toxicity
to ipilimumab.
Overall, 24% of our cohort was sarcopenic before commencing
treatment and 33% of these patients had a low MA. We are not
aware of any other reports that describe the prevalence of
sarcopenia or low MA in patients with metastatic melanoma.
The prevalence of sarcopenia in this cohort is considerably
lower than previously reported for other advanced stage cancers
(Tan et al, 2009; Huillard et al, 2013).
In our study, 56% of patients experienced an irAE of any grade,
while 30% of patients experienced a high-grade irAE (grades III
and IV). The incidence of toxicity in this cohort is similar to those
reported previously (Bertrand et al, 2015; Horvat et al, 2015).
A recent meta-analysis published in 2015, which included 81
articles and a total of 1265 patients from 22 clinical trials (Bertrand
et al 2015), reported the overall incidence of all-grade irAE to be
61% (95% CI: 56–66%) and the incidence of high-grade irAEs to be
17% (95% CI: 10–23%) for patients receiving an ipilimumab dose
of 3 mg kg 1 (Bertrand et al, 2015). Although the incidence of
high-grade irAEs in our study (30%) is higher than reported in the
meta-analysis (17%), it is not uncommon and is similar with that
reported by Horvat et al (2015), where the incidence of high-grade
irAE was reported to be 31% in 298 melanoma patients treated
with 3 mg kg 1 of ipilimumab (Horvat et al, 2015). The prevalence
of toxicity within our study and that of Horvat et al (2015) may be
more representative of patients treated in clinical practice and less
representative of prior clinical trial participants.
We report that patients with sarcopenia were at an increased risk
of experiencing a high-grade AE compared with their non-sarcopenic
counterparts (OR¼ 5.34, 95% CI: 1.15–24.88, P¼ 0.033). Several
other studies reported associations between sarcopenia and increased
chemotherapy toxicity in a variety of cancers including breast (Prado
et al, 2009), colon (Prado et al, 2007), oesophageal (Anandavadivelan
et al, 2015), thyroid (Massicotte et al, 2013) and renal cancer (Huillard
et al, 2013; Cushen et al, 2014). The majority of therapies studied
included anticancer drugs based on body surface area (e.g.,
capecitabine (Prado et al, 2009) and 5-flurouracil (Prado et al, 2007;
Barret et al, 2014; Ali et al, 2016), which has been shown to correlate
weakly with LBM (r2¼ 0.37) (Prado et al, 2008). Additionally,
increased toxicity has been observed in patients with sarcopenia/low
LBM treated with flat-dosed targeted therapies such as sunitinib
(Huillard et al, 2013; Cushen et al, 2014) and vandetanib (Massicotte
et al, 2013).
More recently, reduced MA is increasingly being linked to
poorer clinical outcomes in malignant populations. Sabel et al
(2011) reported low (psoas) MA to be associated with disease-free
(P¼ 0.04) and distant disease-free survival (P¼ 0.0002) in stage III
melanoma patients (Sabel et al, 2011). Martin et al (2013)
supported these findings and reported low MA was predictive of
poorer survival in 1473 lung and GI cancer patients (HR: 1.36, 95%
CI: 1.2–1.6) (Martin et al, 2013). In this study, patients with low
MA were at an increased risk and more frequently experienced
high-grade AEs (OR¼ 5.23, 95% CI: 1.41–19.30, P¼ 0.013; 75% vs
31%, P¼ 0.001) and high-grade irAE (OR¼ 3.57, 95% CI: 1.09–
11.77, P¼ 0.036; 54% vs 23%, P¼ 0.017) compared with those
without low MA. More importantly, these patients were more
susceptible to experience a DLT, either a dose delay or early
cessation of treatment as a result of significant toxicity (37.5% vs
10.4%, P¼ 0.011). However, the explanations for these observa-
tions are unclear. In contrast to these findings, Rollins et al (2015)
found no association between low MA and the incidence of toxicity
or ability to complete palliative chemotherapy in pancreatic cancer
patients (Rollins et al, 2015) and Blauwhoff-Buskermolen et al
(2016) similarly reported no association with baseline sarcopenia
or low MA and treatment modifications (DLT) in metastatic
colorectal cancer patients (Blauwhoff-Buskermolen et al, 2016).
There are few studies examining this relationship. We reported
that patients with a BMI 425 kg m 2 were at an increased risk of
experiencing a high-grade AE (OR¼ 4.01, 95% CI: 1.03–15.69,
P¼ 0.046); however, it is important to note that patients with BMI
425 kg m 2 had a lower MA compared with patients with a
normal BMI (P¼ 0.001), and the increased risk of toxicity is most
likely attributed to the low MA.
Several explanatory mechanisms of increased toxicity in those
with sarcopenia or low lean body mass have been hypothesised
(Antoun et al, 2013a). One potential explanation is pharmacoki-
netic parameter changes induced by malnutrition or obesity, which
could result in alterations in the distribution, metabolism and
clearance of anticancer drugs, increasing the risk of toxic events.
Alternatively, there is a growing body of literature to suggest that
patients with sarcopenia are generally more susceptible to acute
medical events such as infections (Lieffers et al, 2012), post-
operative complications (Peng et al, 2011; van Vugt et al, 2015) and
poorer prognosis (Martin et al, 2013; Montano-Loza et al, 2012).
Another plausible explanation for increased toxicity in patients
with sarcopenia and low MA may be attributed to systemic
inflammation, which is known to underlie both conditions. Rollins
et al (2015) reported that patients with low MA had significantly
greater levels of systemic inflammation (white cell count,
neutrophil–lymphocyte ratio and C-reactive protein) than in those
without low MA (Rollins et al, 2015). Similarly an association
between sarcopenia, low MA and the host inflammatory response
Table 4. Risk of toxicity during ipilimumab treatment in relation to BMI, sarcopenia and low MA determined by multiple logistic
regressions
Model 1a Model 2a
High-grade AE High-grade irAE
n OR 95% CI P-value OR 95% CI P-value
BMI (425 kg m2) 59 4.01 1.03–15.69 0.046 2.46 0.67–9.02 0.173
Sarcopenia 20 5.34 1.15–24.88 0.033 2.17 0.58–8.11 0.248
Low MA 24 5.23 1.41–19.30 0.013 3.57 1.09–11.77 0.036
Abbreviations: AE¼ adverse event; BMI¼body mass index; irAE¼ immune-related adverse event; MA¼Muscle Attenuation.
aAdjusted for gender and age (465 vs o65 years) as potential confounders.
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was observed in a large cohort (n¼ 763) of patients with operable
colorectal cancer (Malietzis et al, 2016).
Treatment toxicity may be as a result of systemic inflammation.
It has been reported that patients with a higher inflammatory
response had an increased risk of severe hematological toxicity
(neutropenic fever or severe thrombocytopenia) following
chemotherapy (Alexandre et al, 2003). Similarly, patients with
inflammation and lymphopenia at baseline were more suscep-
tible to febrile neutropenia following treatment with docetaxel
(Alexandre et al, 2007). Consistent with the expected immune-
stimulating effect of ipilimumab, increases in absolute lympho-
cyte count during treatment have frequently been observed in
melanoma patients (Postow et al, 2013). Ipilimumab may
augment existing systemic inflammation in patients, resulting
in the increased incidence of high-grade AEs in those with
sarcopenia and high-grade AEs, irAEs and DLTs in those
with low MA.
In our study, patients treated with ipilimumab lost on
average 3.32±5.84% of skeletal muscle per 100 days, which is
comparable to 3.1±12%/100 days reported in advanced
pancreatic cancer patients (Tan et al, 2009), but is at a lower
rate compared with ovarian cancer patients undergoing neoad-
juvant chemotherapy (5.2±9.8%/100 days) (Rutten et al,
2016). Other studies have reported significant reductions in
skeletal muscle in a variety of cancer types (Antoun et al, 2010;
Miyamoto et al, 2015; Rollins et al, 2015), but failed to report
these as % change/100 days, which makes it difficult to compare
with our cohort.
Patients with metastatic melanoma with the highest amount
of muscle loss (X7.5% highest quartile) were at a significantly
increased risk of mortality on multivariate analysis (HR: 2.1, 95%
CI: 1.02–4.55; P¼ 0.046). Our results are in line with those
reported in colorectal cancer patients, where a loss of muscle
49% SMA over 3 months of chemotherapy was independently










































































































































































































































































































































































































































































































































































































































































Quartile 4: Highest muscle loss
Quartiles 1–3: Minor muscle loss, stable or gain
Figure 1. Patients with a muscle loss of X7.5%/100 days (quartile four,
highest amount of muscle loss) had significantly lower overall survival
compared with those with a muscle loss o7.5%/100 days (quartiles one
to three; minor muscle loss/stable or gain). Censored cases are
indicated by þ .
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Po0.001) (Blauwhoff-Buskermolen et al, 2016) and a loss of
muscle 42%/100 days was independently associated with
significantly reduced survival in ovarian cancer patients (HR:
1.77, 95% CI: 1.018–3.088, P¼ 0.043) (Rutten et al, 2016). In our
study, sarcopenia and low MA at baseline were
not associated with reduced survival. This is in contrast to some
(Prado et al, 2008; Tan et al, 2009; Martin et al, 2013) but
not all studies (Stene et al, 2015; Blauwhoff-Buskermolen
et al, 2016).
It should be acknowledged that muscle loss is both multi-
factorial and complex, and significant losses of muscle in this
cohort may be attributed to multiple factors. The change in body
composition during ipilimumab treatment may simply reflect the
evolution of systemic disease; however, response to treatment
was not assessed within this patient group. It is often difficult to
evaluate the clinical response in patients treated with immu-
notherapy agents as the patterns of response differ from those
with cytotoxic chemotherapy. Radiologically, patients may have
a transient worsening of disease, before disease stabilises or
regresses and responses in patients can take appreciably longer
to become apparent. In line with this, disease regression is
frequently observed well after the completion of initial induction
period. In addition to catabolic effects caused by the underlying
malignancy and advancing disease, muscle loss may be partially
explained by the potential systemic inflammation caused by
ipilimumab, as well as decreased physical activity and reduced
food intake commonly experienced by patients with advanced
cancer.
The main limitations of our study are its retrospective nature
and relatively small sample size, particularly in the subgroup
analysis. Patients were excluded from the analysis if CT scans
were not available, which may result in selection bias. The mean
time between imaging and initiation of treatment was 39 days
(s.d. 31 days), indicating a few outliers outside the ideal target
window of 30 days. Owing to the exploratory nature of this
study, multiple statistical tests were performed, increasing the
risk of committing type 1 errors. These results should be
regarded as hypothesis-generating and further prospective
studies are needed to validate these results in larger cohort of
metastatic melanoma patients as well as in other cancer types
and treatments.
However, despite the limitations, our results highlight for the
first time the potential use of body composition assessment to
identify patients at increased risk of experiencing severe toxicity
to immunotherapy, that is, ipilimumab. Additionally, this study
reports for the first time the changes in body composition
experienced by patients while undergoing treatment with
ipilimumab, and the adverse effect this has on survival. Potential
treatments to increase muscle mass and their effectiveness to
improve clinical outcomes warrants further investigation. With
the advent of novel immune checkpoint inhibitors showing
significant activity in many solid and liquid tumours, for
example, pembrolizumab and nivolumab in melanoma, lung
cancer, colon cancer, ovarian cancer, bladder cancer, glioblas-
tima, head and neck cancers, and Hodgkin lymphoma (American
Society of Clinical Oncology Education Book 2016), in conjunc-
tion with the lack of validated clinical and molecular biomarkers
that predict response, outcome and toxicity, the importance of
body composition defined by cross-sectional imaging criteria
should not be underestimated.
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